The heart’s remarkable architecture, characterized by its complex chambers and curved surfaces, does not arise from random cellular behaviors but from tightly controlled, region-specific cellular events. The study focuses on cardiomyocytes—the beating heart muscle cells—and reveals how the localized regulation of actomyosin cytoskeletal components influences their shape dynamics during the critical phases of chamber curvature development.

Actomyosin, a molecular motor complex composed of actin filaments and myosin-II motors, plays a pivotal role in generating contractile forces within cells. The researchers demonstrate that within cardiomyocytes, actomyosin organization is not uniform, but instead shows distinct regional patterns correlating with different mechanical and morphological demands. This regionalization enables cardiomyocytes to undergo precise shape changes required for the elaboration of chamber geometry.

The investigators employed cutting-edge live-cell imaging techniques combined with advanced quantitative microscopy to visualize actomyosin architecture in real time during heart development. High-resolution confocal imaging revealed that actomyosin fibers assemble preferentially along specific cellular axes and localize differentially at cell borders, establishing tension gradients that drive anisotropic cell shape remodeling.

Beyond visualization, the team utilized sophisticated biomechanical measurements to link actomyosin organization with force generation within cardiomyocytes. By applying laser ablation and atomic force microscopy, they quantified local mechanical stresses and demonstrated that areas exhibiting enriched actomyosin correspond with zones of heightened contractility, guiding cells toward curved morphologies.

A compelling aspect of this research is the identification of molecular signaling pathways that regulate actomyosin assembly and distribution within cardiomyocytes. The study highlights the roles of Rho GTPases, which orchestrate cytoskeletal dynamics, and upstream mechanotransductive cues derived from the extracellular matrix. These molecular circuits modulate the phosphorylation states of myosin regulatory light chains, fine-tuning contractile activity in a spatially restricted manner.

This region-specific regulation of actomyosin does not function in isolation but is integrated with alterations in cell-cell adhesion and extracellular matrix remodeling. The researchers found that intercellular junctions at sites of curvature formation undergo dynamic adjustments mediated by cadherins, enabling coordinated tissue-level morphogenesis via mechanical coupling of adjacent cardiomyocytes.

Importantly, the authors propose a biomechanical framework wherein localized actomyosin contractility generates asymmetric cortical tension, driving apical constriction and elongation of cardiomyocytes. These shape changes at the single-cell level cumulatively sculpt the macroscopic curves and folds of heart chambers, illuminating a fundamental principle of organ architecture establishment.

The implications of these findings extend beyond developmental biology. Aberrations in actomyosin signaling and organization could underlie congenital defects involving chamber malformations. Moreover, harnessing the knowledge of regionally regulated cytoskeletal dynamics may inform bioengineering strategies aiming to recreate functional cardiac tissues with correct morphology in vitro.

From a technical standpoint, the multidisciplinary approach employed sets a new standard for investigating cytoskeletal mechanisms in vivo. By integrating molecular genetics, live imaging, and physical force measurements, this study achieves a comprehensive understanding of how molecular and mechanical factors converge during cardiac morphogenesis.

Furthermore, the identification of regulatory nodes within the actomyosin pathway opens avenues for targeted therapeutic interventions. Modulating actomyosin contractility pharmacologically or through gene editing could potentially correct developmental defects or improve outcomes in cardiac repair therapies.

In summary, Leerberg and colleagues deliver a seminal contribution that elucidates how spatial regulation of actomyosin underpins the morphogenetic choreography of cardiomyocytes during heart chamber formation. Their insights reveal an elegant interplay between molecular patterning and biophysical forces that orchestrate the emergence of functional cardiac architecture.

This research not only enhances the fundamental understanding of heart development but also paves the way for innovations in congenital heart disease diagnosis, treatment, and tissue engineering. As cardiomyocytes precisely tune their cytoskeletal networks in space and time, the heart emerges as a dynamic symphony of cellular mechanics and molecular signaling, a marvel that science is now beginning to decode.

The intricate dance of actomyosin remodeling within cardiomyocytes stands as a testament to the sophistication of biological design, where regional control of cytoskeletal elements ensures the heart’s chambers take on their life-sustaining curved forms. Future research building on these findings promises to unveil further layers of complexity and biological elegance intrinsic to organogenesis.

As we deepen our grasp of the biomechanical and biochemical principles guiding cardiac tissue shaping, the potential to manipulate these processes for therapeutic ends grows ever more tangible. This study marks a pivotal step on that journey, offering a high-resolution blueprint of cytoskeletal regulation in one of biology’s most vital cellular transformations.

Subject of Research: Regionalized regulation of actomyosin cytoskeleton influencing cardiomyocyte shape changes during heart chamber curvature formation

Article Title: Regionalized regulation of actomyosin organization influences cardiomyocyte cell shape changes during chamber curvature formation

Article References:
Leerberg, D.M., Avillion, G.B., Priya, R. et al. Regionalized regulation of actomyosin organization influences cardiomyocyte cell shape changes during chamber curvature formation. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70384-5

Image Credits: AI Generated

For decades, HLHS has been a black box, frustrating efforts to devise effective treatments beyond palliative surgeries. Traditional models, including simple animal analogs, have failed to capture the multifactorial nature of the syndrome, limiting insights into its molecular genesis and anatomical manifestations. The breakthrough reported in this work stems from the creation of genetically engineered animal models that recapitulate not only the anatomical aberrations seen in HLHS but also mirror the genetic susceptibilities influencing disease onset and progression. This dual-faceted approach promises to propel HLHS research into a new era of precision medicine.

Central to the study’s innovation is the utilization of advanced gene-editing technologies, including CRISPR/Cas9, to introduce mutations in key genes implicated in cardiac development pathways. By targeting loci associated with the proliferation, differentiation, and morphogenesis of cardiac tissues, the researchers engineered phenotypes exhibiting hallmark HLHS features, such as hypoplasia of the left ventricle and aortic valve anomalies. These genetically tailored animal models offer unprecedented opportunities to dissect the temporal cascade of developmental disruptions, from the earliest embryonic stages through postnatal maturation.

Moreover, the study transcends genetic modeling by incorporating detailed anatomical analyses, achieved through high-resolution imaging modalities such as micro-CT and 3D echocardiography. These tools allowed for precise visualization and quantification of the structural deformities, enabling a deeper understanding of how genetic mutations translate into gross morphological defects. The integration of anatomical data with genomic profiles facilitated the correlation of specific gene variants with distinct anatomical phenotypes, illuminating the heterogeneity within HLHS presentations.

The selection of species for modeling was strategic, balancing physiological similarity to humans with practical considerations such as gestational timeline and genetic tractability. The research predominantly focused on murine and porcine models. Mice have long been a staple in genetic research due to their well-characterized genome and ease of manipulation, while pigs offer a closer approximation to human cardiac anatomy and physiology. Together, these models offered complementary platforms to explore the complex interplay between genetic aberrations and cardiac development.

A particularly striking aspect of this study lies in the epigenetic dimensions explored. Beyond the static DNA sequence, the team examined how modifications to chromatin accessibility and DNA methylation patterns influence gene expression during critical windows of heart formation. By using techniques like ATAC-seq and bisulfite sequencing in their models, they demonstrated that epigenetic dysregulation magnifies the phenotypic severity of HLHS, suggesting new avenues for therapeutic intervention targeting the epigenome.

Furthermore, the models uncovered novel gene candidates not previously linked to HLHS, expanding the repertoire of molecular players involved in cardiac hypoplasia. Through transcriptomic analyses using RNA sequencing, the study highlighted pathways related to extracellular matrix remodeling, angiogenesis, and cell cycle regulation. These findings reveal a complex network of interactions that orchestrate normal left heart development and how their disruption culminates in HLHS.

The translational implications of this work are profound. With these models, researchers can now test targeted therapies in a preclinical setting with enhanced predictive power. For example, pharmacological agents aimed at rescuing myocardial proliferation or modulating specific signaling cascades can be evaluated for efficacy and safety. Additionally, gene therapy approaches hold greater promise, as these animal models provide a critical proving ground for delivery methods and long-term outcomes.

This modeling strategy also opens avenues for personalized medicine in pediatric cardiology. Understanding the genetic and anatomical diversity within HLHS patients allows for tailoring surgical interventions and post-operative care based on individual risk profiles. The researchers envision a future where newborns diagnosed prenatally with HLHS could benefit from bespoke treatment plans grounded in the insights derived from these animal models.

Importantly, the study acknowledges ethical and technical challenges. Creating animal models that faithfully replicate human congenital defects requires rigorous validation and adherence to the highest standards of animal welfare. The investigators emphasize the importance of transparency and reproducibility in their methods, ensuring that their models serve as reliable tools for the broader scientific community.

Equally transformative is the potential impact on in utero therapies. The detailed understanding of the developmental trajectory of HLHS gleaned from these models paves the way for fetal interventions designed to correct or mitigate the anatomical defects before birth. Although still in early experimental stages, such approaches could dramatically improve survival rates and quality of life for affected infants.

Moreover, the study inspires a multidisciplinary approach, combining genetics, developmental biology, cardiology, imaging science, and bioinformatics. This synthesis exemplifies how contemporary biomedical research thrives at the intersection of diverse expertise, driving innovations that single-discipline efforts could not achieve.

From a broader perspective, the methodologies refined in developing these HLHS models have implications for other congenital heart defects and developmental diseases. The paradigm of integrating targeted genetic modifications with precise anatomical characterization sets a new standard for modeling complex human conditions.

As with any scientific advance, questions remain. The exact mechanisms by which specific gene-environment interactions shape the HLHS phenotype need further elucidation. Additionally, long-term studies tracking functional outcomes and compensatory mechanisms in the animal models will deepen insights into disease progression and resilience.

Nevertheless, this landmark research signifies a pivotal step toward unraveling the enigmatic origins of hypoplastic left heart syndrome. By bridging the genetic and anatomical facets of the disorder, it offers renewed hope for patients, families, and clinicians grappling with this formidable condition. The promise of translating these findings into tangible clinical benefits fuels ongoing efforts and collaboration worldwide.

In conclusion, the innovative animal models engineered by Miyagi, Nakamae, Davis, et al., represent a tour de force in congenital heart disease research. Their work epitomizes the power of integrating genetic precision with anatomical realism, charting a path toward breakthroughs in understanding, diagnosing, and ultimately treating hypoplastic left heart syndrome. The scientific community watches with anticipation as these models catalyze further discoveries and bring us closer to conquering one of pediatric cardiology’s most intractable challenges.

Subject of Research: Hypoplastic left heart syndrome (HLHS) and its genetic and anatomical modeling in animal species.

Article Title: Animal models of hypoplastic left heart syndrome: genetic and anatomical approaches.

Article References:
Miyagi, C., Nakamae, K., Davis, M.E. et al. Animal models of hypoplastic left heart syndrome: genetic and anatomical approaches. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04815-w

Image Credits: AI Generated

DOI: 03 March 2026

Dr. Gelb’s career embodies a deep commitment to unraveling the complex genetic architecture underpinning congenital heart disease (CHD), a leading cause of morbidity and mortality in children worldwide. His comprehensive research portfolio bridges the clinical and molecular domains, illuminating genetic variants responsible for CHD and associated developmental syndromes. Over decades, his laboratory at Mount Sinai has leveraged high-throughput sequencing technologies, genomics, and rigorous phenotypic characterization to decode the multifactorial etiology of these disorders, shifting paradigms within pediatric cardiology and genetic medicine.

A faculty member at Mount Sinai since 1991, Dr. Gelb has been instrumental in cultivating an international reputation for genomic discovery in pediatric populations. His work notably advances understanding of Noonan syndrome and related RASopathies—a cluster of disorders caused by mutations affecting the RAS-MAPK signaling pathway, which regulates cellular proliferation, differentiation, and apoptosis during embryogenesis. These insights have significant clinical implications, improving diagnostic precision and offering potential therapeutic targets for these previously enigmatic conditions.

Among his many contributions, Dr. Gelb co-led a groundbreaking study elucidating gene-pair interactions responsible for digenic inheritance in CHD. This revelation expands the genetic paradigm beyond monogenic models, illustrating how the concomitant inheritance of variants in two genes synergistically disrupts normal heart development. The application of advanced bioinformatics and integrative genomic approaches in this research has paved new avenues for tailored genetic counseling and personalized medicine strategies for affected families.

Beyond his research, Dr. Gelb’s leadership at the Mindich Child Health and Development Institute has established a multidisciplinary hub where genetics, artificial intelligence, clinical trials, and health services research converge. His visionary direction fosters an ecosystem optimizing translational research, accelerating the conversion of scientific discoveries into clinical interventions that address pediatric health disparities and improve long-term outcomes for children with congenital disorders.

Peers and institutional leaders laud Dr. Gelb not only for his scientific prowess but also for his commitment to mentorship. As Eric J. Nestler, MD, PhD, Dean of the Icahn School of Medicine at Mount Sinai, emphasizes, Dr. Gelb exemplifies the ideal physician-scientist archetype, marrying rigorous investigation with compassionate clinical care and fostering a new generation of pediatric researchers dedicated to advancing child health.

Dr. Gelb’s influence permeates national pediatric research communities through his leadership roles, including past presidencies of both the American Pediatric Society and the American Society of Human Genetics. Additionally, as the inaugural president of the Pediatric Academic Societies Board, he played a foundational role in unifying diverse pediatric research domains under a single strategic vision, enhancing collaborative networks and resource sharing across institutions.

His election to the National Academy of Medicine underscores the broad societal impact of his contributions, reflecting recognition from the highest echelons of healthcare and scientific policy. This membership facilitates his ongoing involvement in providing evidence-based recommendations on health-related matters, further affecting pediatric healthcare policies and research priorities on a national scale.

Mount Sinai Health System celebrates this honor as a testament to its enduring commitment to excellence in pediatric research and clinical innovation. Through such recognitions, the institution reinforces its mission to push the boundaries of biomedical science, nurturing an environment where transformative insights into pediatric diseases continuously emerge.

The field of pediatric cardiology and genetics stands at a crucial inflection point, buoyed by Dr. Gelb’s advancements that integrate sophisticated genomic technologies with clinical acumen. These developments not only deepen fundamental understanding of developmental biology but also lay the groundwork for novel diagnostic tools and targeted interventions that promise to reduce the burden of congenital heart defects and associated syndromes globally.

As the broader medical community anticipates the upcoming Pediatric Academic Societies Meeting, Dr. Gelb’s award serves as both a celebration of past achievements and an inspiration for future innovation. His career underscores the vital interplay between basic scientific inquiry and translational medicine in addressing complex pediatric health challenges that demand interdisciplinary approaches and sustained collaboration.

In summary, Dr. Bruce D. Gelb’s selection as the 2026 APS John Howland Award recipient highlights a career replete with transformative discoveries in pediatric genetics and cardiology. His legacy continues to influence clinical practice paradigms and research trajectories, ultimately improving the lives of countless children worldwide born with congenital heart disease and developmental disorders.

Subject of Research: Pediatric genetics and cardiology, congenital heart disease, RASopathies, gene-gene interactions in developmental disorders

Article Title: American Pediatric Society Honors Bruce D. Gelb, MD, with 2026 John Howland Award for Groundbreaking Work in Pediatric Cardiology and Genetics

News Publication Date: October 29, 2025

Web References:

• https://www.aps1888.org/
• https://www.aps1888.org/awards/#top

Image Credits: Mount Sinai Health System

Keywords: Pediatrics, Genetics, Congenital Heart Disease, RASopathies, Pediatric Cardiology, Genomics, Gene Discovery, Digenic Inheritance, Child Health Research, Pediatric Academic Societies, Mount Sinai

The John Howland Award, established in 1952 to honor the legacy of clinician-scientist John Howland, MD, recognizes individuals whose careers have significantly advanced the field of academic pediatrics. Dr. Gelb’s selection underscores the critical importance of genetic research in transforming the diagnosis, management, and treatment of pediatric congenital anomalies, particularly within cardiology. The award ceremony is scheduled for the APS Presidential Plenary at the Pediatric Academic Societies (PAS) Meeting in Boston, 2026.

Dr. Gelb’s scientific journey has been characterized by pioneering efforts to decode the genetic architecture of congenital heart defects, a leading cause of neonatal morbidity and mortality globally. His seminal work, supported by the National Institutes of Health, identified crucial molecular mechanisms that explain why certain cardiac malformations arise during embryonic development. Notably, Dr. Gelb’s discovery of the first genetic mutations responsible for Noonan syndrome—a condition marked by diverse cardiac and developmental abnormalities—has illuminated the broader category of RASopathies, a group of disorders driven by disruptions in the RAS-MAPK signaling pathway. These findings have catalyzed advances in precision medicine approaches, enabling clinicians to better predict disease trajectories and tailor interventions accordingly.

The implications of Dr. Gelb’s research extend beyond molecular genetics; his contributions have reshaped clinical paradigms by integrating genetic diagnosis into routine pediatric cardiology practice. By leveraging next-generation sequencing technologies and comprehensive genotype-phenotype correlations, his work has influenced the development of novel screening protocols and therapeutic strategies aimed at mitigating the long-term complications of CHD. This translational impact exemplifies the convergence of bench research and bedside care that defines modern pediatrics.

Stephen R. Daniels, MD, PhD, President of the American Pediatric Society, lauded Dr. Gelb as a paragon of scientific innovation combined with visionary leadership. He emphasized Dr. Gelb’s commitment not only to advancing knowledge but also to mentoring the next wave of pediatric physician-scientists. During his APS presidency, Dr. Gelb spearheaded a strategic transformation, mobilizing the society’s resources towards impactful action-oriented initiatives that address pressing child and adolescent health challenges.

Beyond his research milestones, Dr. Gelb has played a pivotal role in fostering interdisciplinary collaboration through his leadership as founding Director of the Mindich Child Health and Development Institute. At Mount Sinai, he cultivated a robust research ecosystem that integrates clinical investigation, health services research, and cutting-edge artificial intelligence applications to enhance pediatric care delivery and outcomes. This integrative approach reflects a forward-thinking vision that anticipates the future of child health research.

Dr. Gelb’s advocacy for pediatric research is further exemplified by his extensive service in national and international academic organizations. His tenure on the APS Council and his role as Program Chair for the Pediatric Academic Societies meetings have fortified the scientific community’s infrastructure, ensuring sustainable funding, policy development, and community engagement. As the inaugural President of the PAS Board, he was instrumental in architecting governance models that continue to underpin the society’s effectiveness.

In molecular genetics, Dr. Gelb’s emphasis on elucidating pathophysiological mechanisms at the cellular and genetic levels has bridged fundamental biology with clinical application. By dissecting the genetic pathways implicated in heart development and function, his work has propelled translational research initiatives, facilitating clinical trials of targeted therapies and informing genetic counseling practices for affected families.

His efforts have also highlighted the importance of integrating genomic data with environmental and epigenetic factors, expanding the scientific community’s understanding of how complex interactions contribute to congenital anomalies. This holistic perspective is essential for the development of comprehensive intervention strategies that encompass prevention, early diagnosis, and personalized treatment.

The impact of Dr. Gelb’s legacy is poised to resonate for decades, as he cultivates future leaders and drives continuous innovation in pediatric medicine. His journey embodies the mission of the American Pediatric Society: to nurture leadership, champion innovation, and foster scientific excellence that ultimately enhances the health and well-being of children worldwide.

As the APS prepares to celebrate Dr. Gelb’s achievements at the 2026 PAS Meeting, the pediatric and genetic research communities are reminded of the transformative power of combining scientific rigor with compassionate leadership. His work not only unravels the mysteries of congenital heart disease but also sets the stage for a new era of precision pediatric care informed by genetics and molecular biology.

The conferment of the John Howland Award to Dr. Gelb represents a beacon of inspiration for clinicians and researchers alike, affirming the vital role of academic pediatrics in pushing the boundaries of medical knowledge and improving child health outcomes on a global scale.

Subject of Research: Pediatric cardiology, molecular genetics, congenital heart disease, genetic causes of developmental disorders, RASopathies

Article Title: Dr. Bruce D. Gelb Awarded 2026 John Howland Award for Groundbreaking Genetic Discoveries in Pediatric Cardiology

News Publication Date: October 28, 2025

Web References:
– American Pediatric Society: http://www.aps1888.org/
– American Pediatric Society Facebook: https://www.facebook.com/AmerPedSoc/
– American Pediatric Society Twitter: https://twitter.com/AmerPedSociety

Image Credits: APS

Keywords: Pediatrics, Cardiology, Genetic disorders, Research organizations, Clinical research, Congenital heart disease, Molecular genetics, Noonan syndrome, RASopathies, Pediatric academic leadership, Precision medicine, Child health research

Recent scientific advancements have shed light on the intricate mechanisms underlying congenital heart defects (CHDs) associated with Down syndrome (DS), a genetic condition caused by the presence of an extra copy of chromosome 21. Approximately 2,600 children born each year in the United States with DS also exhibit various heart anomalies, predominantly atrioventricular canal (AVC) defects. This alarming statistic underscores the urgent need for a deeper understanding of how the overexpression of genes on chromosome 21 plays a critical role in the etiology of these heart defects.

In a groundbreaking study published in the prestigious journal Nature, a team of scientists, led by Dr. Sanjeev S. Ranade of Sanford Burnham Prebys, identified High Mobility Group Nucleosome Binding Protein 1, or HMGN1, as a pivotal contributor to DS-related congenital heart defects. This revelation not only addresses the longstanding question of why trisomy 21 is linked to devastating health issues but also opens new avenues for targeted therapies aimed at ameliorating these conditions.

The researchers embarked on this compelling journey by exploring the roles of specific genes on chromosome 21 that may exacerbate the effects of having an extra copy. Dr. Ranade articulated the research’s primary question: “What are the genes on chromosome 21 that are detrimental in triplicate?” By employing cutting-edge technologies, including CRISPR activation, the research team meticulously elevated the expression levels of chromosome 21 genes, facilitating the conversion of normal cells into a phenotype resembling that of Down syndrome cells.

HMGN1 is a multifaceted protein integral to various cellular processes, including the binding of nucleosomes—the foundational units of chromatin that package DNA within the cell nucleus. Its functions extend to the regulation of gene expression and the facilitation of crucial DNA replication and repair mechanisms. HMGN1’s presence was notably abundant in cells affected by trisomy 21, indicating its potential role as an instigator of the cardiac malformations observed in affected individuals.

Utilizing human pluripotent stem cells alongside mouse models of Down syndrome, the research yielded promising results. When HMGN1 levels were elevated, the differentiation of developing AVC cardiomyocytes veered toward an abnormal trajectory, prompting concerns about cardiac structural integrity. Conversely, the targeted deletion of one allele of HMGN1 in trisomic cells resulted in the restoration of normal gene expression, suggesting that moderation of this protein could pivotal in rectifying certain cardiac defects.

The significance of these findings cannot be overstated. Prior to this study, the direct correlation between HMGN1 and heart defects in the context of Down syndrome remained inadequately elucidated. This advancement provides a framework for comprehending the genetic underpinnings of other associated conditions, such as bone malformations and intellectual disabilities common in individuals with Down syndrome. The research fuels hope for the development of pharmacological interventions that may counteract the negative effects of an extra chromosome 21, leveraging the insights gleaned from the intricate functions of HMGN1.

The implications of this study resonate beyond congenital heart defects alone. With about 40,000 children born with CHDs each year in the United States, understanding the genetic factors involved can pave the way for innovative treatment strategies. Whether through pharmaceutical targeting or gene-editing technologies, the potential to address such a critical health issue offers a beacon of hope to families affected by these conditions.

Dr. Deepak Srivastava, a prominent figure at the Gladstone Institutes and UC San Francisco, served as the study’s senior author. His collaboration with Dr. Ranade and their team showcases the power of interdisciplinary efforts in unraveling complex genetic questions. Notably, the study garnered substantial support from various esteemed organizations, including the National Institutes of Health, emphasizing the collective commitment to addressing congenital disorders through rigorous scientific inquiry.

As the research community is reminded of the profound complexities of genetic disorders such as Down syndrome, the current study highlights the importance of creating a roadmap for identifying genes that may drive other congenital anomalies. The findings may serve not only as a catalyst for further research into cardiac defects but also spur developments in understanding other genetic conditions that warrant similar exploration. Ultimately, the goal is clear: to translate this knowledge into practical interventions that will significantly improve the lives of those affected by Down syndrome and its associated challenges.

In conclusion, the pivotal role of HMGN1 in trisomy 21-related heart defects presents a compelling narrative of hope and potential advancement in the field of genetic medicine. Continued research in this domain promises to unravel the mysteries surrounding other genetic disorders, enhancing our ability to treat and even prevent conditions that have long posed complex challenges to medical professionals and affected families alike.

Subject of Research: Down Syndrome and Congenital Heart Defects
Article Title: Myocardial reprogramming by HMGN1 underlies heart defects in trisomy 21
News Publication Date: 22-Oct-2025
Web References: Nature Article
References: Details not available
Image Credits: Credit: Sanford Burnham Prebys

Keywords

• Down syndrome
• Genetic disorders
• Chromosomal abnormalities
• Medical genetics
• Congenital defects
• Cardiac function
• Heart defects
• DNA repair
• Gene expression
• Molecular genetics